Get a Clue - Weed

Details: Published: 15 January 2025; Hits: 444

caredu The rising prevalence of cannabis use, fuelled by its legalisation in many areas, is creating a significant road safety crisis. While society has long recognised the dangers of drink-driving, the risks associated with cannabis-impaired driving are not as widely understood, leaving communities vulnerable to preventable tragedies on the road.

The Challenges of Detecting Cannabis-Impaired Driving

One of the most pressing issues in addressing cannabis-impaired driving is the lack of reliable testing methods. Unlike alcohol, where blood-alcohol concentration levels are a proven indicator of impairment, there is no universally accepted standard to measure how recent cannabis use affects driving ability.

Existing blood tests can detect THC, the psychoactive compound in marijuana, but they fail to determine when it was consumed. THC lingers in the bloodstream long after its intoxicating effects have worn off, making current tests inaccurate for determining impairment. This gap gives cannabis-impaired drivers an unjust opportunity to escape accountability.

Additionally, portable devices capable of detecting cannabis use, akin to alcohol breathalysers, are still in development. Without such tools, law enforcement is left with limited means to identify cannabis-impaired drivers, exposing all road users to heightened risks.

Confusion in Cannabis Driving Laws

The legal frameworks surrounding cannabis and driving vary widely across regions, further complicating enforcement. Some states have adopted “zero-tolerance” policies, while others have implemented limits for THC levels in the bloodstream. However, these limits are not grounded in a clear understanding of how cannabis affects impairment, leaving them inadequate for ensuring safety.

Unlike alcohol, which universally impairs reflexes and judgement, the effects of cannabis differ depending on how it is consumed. Smoked cannabis takes effect quickly but wears off rapidly, while edibles produce longer-lasting but delayed effects. Compounding this is the tolerance developed by frequent users, which can mask conventional signs of impairment yet still put them at risk behind the wheel.

This inconsistency and lack of clarity leave drivers uncertain and underinformed, often resulting in dangerous behaviour on the road.

How Cannabis Use Impacts Driving Ability

Cannabis is known to adversely affect a driver’s ability to react to obstacles, judge distance, and make safe decisions. These impairments may not always manifest in the aggressive behaviour typically associated with drink-driving but can be equally dangerous. For example, cannabis users tend to drive slower, which some might interpret as caution. However, this perceived caution often disguises their impaired reflexes and focus.

Mounting evidence highlights the perils created by cannabis-impaired drivers. Surveys indicate a growing number of users admitting to driving after consuming marijuana, with many falsely believing that the drug either has no impact or even improves their driving performance. This misconception only amplifies the risks on our roads.

The Hidden Cost of Poor Enforcement

The rise in tragic cannabis-related accidents underscores the consequences of inconsistent laws and inadequate enforcement tools. Families who have lost loved ones in crashes involving marijuana-impaired drivers often find themselves grappling with injustice, as current legal frameworks fail to hold culprits fully accountable.

For instance, THC levels in blood samples taken after accidents cannot pinpoint if a driver was impaired at the time of the crash. This compounding issue means culpable drivers frequently evade responsibility, while victims’ families and communities bear the heart-wrenching fallout. Weak sentencing and blurred legal standards have fuelled a sense of public frustration and mistrust, underscoring the urgent need for reform.

Why Stronger Policies Are Vital

The devastating impact of cannabis-impaired driving highlights the need for stronger, clearer policies to protect road users and save lives. Legislative efforts focusing on accommodating cannabis use fail to address its inherent dangers, prioritising personal freedoms over societal safety. Without decisive action, the number of lives lost to cannabis-related accidents will only continue to rise.

Public education also plays a critical role in challenging misconceptions about cannabis and driving. It is essential to dismantle the myth of “safe” drug use behind the wheel and remind individuals that choosing to drive while impaired by any substance puts countless innocent lives at risk.

Keeping Safety as the Top Priority

Drug use and driving simply do not mix, yet the growing normalisation of cannabis is creating a dangerous illusion of safety on the roads. It is imperative that public safety takes precedence over the normalisation or commercialisation of substances like marijuana. By advocating zero tolerance for impairment on the roads, we can chart a course towards safer streets, better accountability, and a stronger commitment to protecting lives.

The message is simple yet critical—there is no safe way to drive under the influence of cannabis or any other substance. It’s time for society to unite in prioritising the safety of our roads for everyone. (WRD News)

Also see Cannabis and Driving: Victorian Law Change for ‘Medicinal’ Cannabis Users – But is Road Safety Seriously Compromised?

Details: Published: 15 January 2025; Hits: 447

buds The expansion of cannabis legalisation across various states has sparked growing concerns about its impact on public health. Recent studies reveal alarming increases in cannabis use disorder (CUD) and cannabis poisoning, particularly in states where medical and recreational cannabis have been legalised. These findings cast doubt on the widely-touted benefits of legalisation, while exposing the significant healthcare and societal challenges linked to increased cannabis use.

Cannabis Legalisation and Rising Health Concerns: Evidence from a decade-long study (2011-2021) shows a sharp rise in cannabis-related diagnoses following legalisation. States with medical cannabis laws experienced a staggering 42.7% increase in CUD and an even more alarming 88.6% rise in cannabis poisoning cases. Similarly, recreational cannabis laws contributed to a 31.6% spike in poisonings.

These statistics highlight a worrying trend—legalising cannabis appears to pave the way for greater health risks, particularly among adults with easier access to the drug. Women and individuals aged 35 to 44 were identified as particularly vulnerable, showing higher rates of cannabis addiction compared to other groups.

The Healthcare Impact of Increased Cannabis Use: The rise in CUD and cannabis poisoning has serious implications for healthcare systems. Communities with legal cannabis have seen a significant strain on their medical resources, driven by the costs and demand for treatments linked to cannabis-related health issues. From emergency visits caused by poisoning to longer-term care for CUD, the effects ripple outward, burdening not just healthcare providers but families and society at large.

Is Cannabis Legalisation a Double-Edged Sword?: While proponents often celebrate cannabis legalisation for its economic and medicinal benefits, these findings underline the often-overlooked risks. Increased access to cannabis can lead to normalised use, inadvertently fuelling addiction and public health crises. The rapid rise in diagnoses associated with cannabis underscores the need for stricter controls and greater public awareness of the potential dangers.

Protecting Communities Through Vigilance: The findings call for a renewed focus on public health and safety when it comes to drug policy. With evidence pointing to the harmful impacts of cannabis legalisation—including spikes in CUD and poisoning—it is clear that safeguards must be prioritised. Education, awareness, and careful review of existing policies are essential to curb the unintended consequences and ensure that communities remain healthy and safe.

By closely monitoring the consequences of cannabis legalisation and pushing for proactive measures, we can better protect society against the risks tied to this controversial substance.

(Source: Jama Network)

Details: Published: 14 January 2025; Hits: 454

holdweed New research sheds critical light on the connection between frequent cannabis use and the risk of developing psychosis. Conducted by King’s College London’s Institute of Psychiatry, Psychology & Neuroscience (IoPPN) and South London and Maudsley NHS Foundation Trust, the study reveals that cannabis use independently raises the likelihood of psychosis, irrespective of one’s genetic predisposition to schizophrenia. This poses significant concerns, particularly in the face of rising cannabis use and the increased potency of products available today.

Frequent Use and High Potency Carry the Greatest Risks

The study examined the impact of lifetime frequent cannabis use and found a clear link to psychosis. This risk was particularly high among those who reported daily use of high-potency cannabis, defined as products containing 10% or more of THC (Delta-9 tetrahydrocannabinol). THC is the psychoactive compound predominantly responsible for the drug’s intoxicating effects.

Though the study investigated genetic predisposition to schizophrenia using polygenic risk scores (PRSs), it demonstrated that the risk from frequent cannabis use operates independently. Simply put, the environmental danger from using cannabis is significant enough to raise the likelihood of psychosis on its own.

Genetic and Environmental Risks Act Separately

Researchers emphasised an important finding — genetic vulnerability to schizophrenia and cannabis use do not appear to interact, but rather influence the risk of psychosis through separate mechanisms. This means someone with no genetic predisposition to schizophrenia may still develop psychosis through frequent or high-potency cannabis use. While there may be an additive effect for those with both genetic risk and a history of heavy use, the study highlights that cannabis alone is a considerable factor. (Source: WRD News)

Also see

Details: Published: 14 January 2025; Hits: 822

K2, Spice, and other similar terms refer to synthetic designer drugs that mimic the effects of THC, the main psychoactive compound found in cannabis. These substances, however, are far from natural. Synthetic cannabinoids are lab-created chemicals sprayed onto plant material, often marketed as “herbal incense” or “potpourri” and labelled “not for human consumption” to dodge legal scrutiny. Despite these warnings, they are widely abused for their psychoactive properties.

These substances are often deceptively packaged with alluring designs and sold in convenience stores, petrol stations, and online. The origins of these products are usually unknown, with the chemicals they contain being produced in unregulated laboratories, primarily in Asia, without any quality control or safety standards. For complete article The Dangers of K2/Spice - WRD News (also see DEA on K2)

Details: Published: 10 December 2024; Hits: 743

Abstract

Background: The association between cannabis and psychosis is established, but the role of underlying genetics is unclear. We used data from the EU-GEI case-control study and UK Biobank to examine the independent and combined effect of heavy cannabis use and schizophrenia polygenic risk score (PRS) on risk for psychosis.

Methods: Genome-wide association study summary statistics from the Psychiatric Genomics Consortium and the Genomic Psychiatry Cohort were used to calculate schizophrenia and cannabis use disorder (CUD) PRS for 1098 participants from the EU-GEI study and 143600 from the UK Biobank. Both datasets had information on cannabis use.

Results: In both samples, schizophrenia PRS and cannabis use independently increased risk of psychosis. Schizophrenia PRS was not associated with patterns of cannabis use in the EU-GEI cases or controls or UK Biobank cases. It was associated with lifetime and daily cannabis use among UK Biobank participants without psychosis, but the effect was substantially reduced when CUD PRS was included in the model. In the EU-GEI sample, regular users of high-potency cannabis had the highest odds of being a case independently of schizophrenia PRS (OR daily use high-potency cannabis adjusted for PRS = 5.09, 95% CI 3.08–8.43, p = 3.21 × 10−10). We found no evidence of interaction between schizophrenia PRS and patterns of cannabis use.

Conclusions: Regular use of high-potency cannabis remains a strong predictor of psychotic disorder independently of schizophrenia PRS, which does not seem to be associated with heavy cannabis use. These are important findings at a time of increasing use and potency of cannabis worldwide. (Source: Psychological Medicine December 2024, Cambridge University Press)

Also see